Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sepracor working with SmithKline on R-ketoprofen OTC analgesic project.

This article was originally published in The Tan Sheet

Executive Summary

SEPRACOR WORKING WITH SMITHKLINE ON R-KETOPROFEN OTC ANALGESIC PROJECT, Sepracor Chief Financial Officer David Southwell told securities analysts at the Dillon, Read generic drug and drug delivery conference in New York City May 11. SmithKline Beecham has recently taken over the project following its acquisition of the Sterling Winthrop OTC business outside the U.S. Sepracor and Sterling signed a co-development agreement on the single-isomer version of ketoprofen in December 1992, under which Sterling received worldwide OTC marketing rights.
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS083851

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel